Invesco BulletShares 2033 High Yield Corporate Bond ETF (BSJX)
Live price chart, market sentiment, and community perspectives for Invesco BulletShares 2033 High Yield Corporate Bond ETF (NASDAQ: BSJX).
Live price chart, market sentiment, and community perspectives for Invesco BulletShares 2033 High Yield Corporate Bond ETF (NASDAQ: BSJX).
On our desk, evaluating BSJX comes down to recognizing that while the underlying fixed-income mechanics look healthy—boasting a 6.76% yield to maturity and a 6.83% weighted coupon—the tiny $20.1M market cap is an immediate red flag for trading flexibility. Institutional activity shows 12 filers holding about $14.3M in Q2 2026, but the liquidity profile remains thin. If you are buying this target-maturity vehicle, you must treat it strictly as a buy-and-hold allocation to 2033. Trying to trade in and out of a vehicle this small will eat away at any yield advantage via wide bid-ask spreads.
When analyzing target-maturity high-yield ETFs like BSJX for a fixed-income portfolio strategy, my protocol is to verify both the constituent credit quality and the secondary market liquidity constraints. With a weighted price near 99.65 and an effective maturity of 6.85 years, the fund offers clear mathematical convergence toward 2033. However, because institutional ownership sits at roughly 8 to 12 filers holding a cumulative $14.3M to $19M across quarters, analysts must model execution slippage carefully. Early exits are punished by the lack of deep secondary market depth.
From a strict risk-analysis standpoint, BSJX presents an interesting paradox. It registers a low Morningstar risk score or conservative volatility profile historically, with a 1-year beta of 0.26 and an effective duration around 4.19. However, the asset base is exceptionally constrained at $20.1M. The underlying index holds U.S. dollar-denominated junk bonds maturing in 2033 with an average credit rating of BB-, meaning credit risk is present even if target-maturity mechanics help derisk the duration approach as the target year draws closer.
Explore plasma cleansing, somatic organ swaps, and BCI.